CCR5 Governs DNA damage repair and breast cancer stem cell expansion

Xuanmao Jiao, Marco A. Velasco-Velazquez, Min Wang, Zhiping Li, Hallgeir Rui, Amy R. Peck, James Korkola, Xuelian Chen, Shaohua Xu, James B. DuHadaway, Sandra Guerrero-Rodriguez, Sankar Addya, Daniela Sicoli, Zhaomei Mu, Gang Zhang, Andres Stucky, Xi Zhang, Massimo Cristofanilli, Alessandro Fatatis, Joe GrayJiang F. Zhong, George C. Prendergast, Richard G. Pestell

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The functional significance of the chemokine receptor CCR5 in human breast cancer epithelial cells is poorly understood. Here, we report that CCR5 expression in human breast cancer correlates with poor outcome. CCR5þ breast cancer epithelial cells formed mammospheres and initiated tumors with >60-fold greater efficiency in mice. Reintroduction of CCR5 expression into CCR5-negative breast cancer cells promoted tumor metastases and induced DNA repair gene expression and activity. CCR5 antagonists Maraviroc and Vicriviroc dramatically enhanced cell killing mediated by DNA-damaging chemotherapeutic agents. Single-cell analysis revealed CCR5 governs PI3K/Akt, ribosomal biogenesis, and cell survival signaling. As CCR5 augments DNA repair and is reexpressed selectively on cancerous, but not normal breast epithelial cells, CCR5 inhibitors may enhance the tumor-specific activities of DNA damage response–based treatments, allowing a dose reduction of standard chemotherapy and radiation. Significance: This study offers a preclinical rationale to reposition CCR5 inhibitors to improve the treatment of breast cancer, based on their ability to enhance the tumor-specific activities of DNA-damaging chemotherapies administered in that disease.

Original languageEnglish (US)
Pages (from-to)1657-1671
Number of pages15
JournalCancer Research
Volume78
Issue number7
DOIs
StatePublished - Apr 1 2018

Fingerprint

Neoplastic Stem Cells
DNA Repair
DNA Damage
Breast Neoplasms
Epithelial Cells
Neoplasms
Single-Cell Analysis
Drug Therapy
Chemokine Receptors
DNA
Phosphatidylinositol 3-Kinases
Cell Survival
Breast
Radiation
Neoplasm Metastasis
Gene Expression
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jiao, X., Velasco-Velazquez, M. A., Wang, M., Li, Z., Rui, H., Peck, A. R., ... Pestell, R. G. (2018). CCR5 Governs DNA damage repair and breast cancer stem cell expansion. Cancer Research, 78(7), 1657-1671. https://doi.org/10.1158/0008-5472.CAN-17-0915

CCR5 Governs DNA damage repair and breast cancer stem cell expansion. / Jiao, Xuanmao; Velasco-Velazquez, Marco A.; Wang, Min; Li, Zhiping; Rui, Hallgeir; Peck, Amy R.; Korkola, James; Chen, Xuelian; Xu, Shaohua; DuHadaway, James B.; Guerrero-Rodriguez, Sandra; Addya, Sankar; Sicoli, Daniela; Mu, Zhaomei; Zhang, Gang; Stucky, Andres; Zhang, Xi; Cristofanilli, Massimo; Fatatis, Alessandro; Gray, Joe; Zhong, Jiang F.; Prendergast, George C.; Pestell, Richard G.

In: Cancer Research, Vol. 78, No. 7, 01.04.2018, p. 1657-1671.

Research output: Contribution to journalArticle

Jiao, X, Velasco-Velazquez, MA, Wang, M, Li, Z, Rui, H, Peck, AR, Korkola, J, Chen, X, Xu, S, DuHadaway, JB, Guerrero-Rodriguez, S, Addya, S, Sicoli, D, Mu, Z, Zhang, G, Stucky, A, Zhang, X, Cristofanilli, M, Fatatis, A, Gray, J, Zhong, JF, Prendergast, GC & Pestell, RG 2018, 'CCR5 Governs DNA damage repair and breast cancer stem cell expansion', Cancer Research, vol. 78, no. 7, pp. 1657-1671. https://doi.org/10.1158/0008-5472.CAN-17-0915
Jiao X, Velasco-Velazquez MA, Wang M, Li Z, Rui H, Peck AR et al. CCR5 Governs DNA damage repair and breast cancer stem cell expansion. Cancer Research. 2018 Apr 1;78(7):1657-1671. https://doi.org/10.1158/0008-5472.CAN-17-0915
Jiao, Xuanmao ; Velasco-Velazquez, Marco A. ; Wang, Min ; Li, Zhiping ; Rui, Hallgeir ; Peck, Amy R. ; Korkola, James ; Chen, Xuelian ; Xu, Shaohua ; DuHadaway, James B. ; Guerrero-Rodriguez, Sandra ; Addya, Sankar ; Sicoli, Daniela ; Mu, Zhaomei ; Zhang, Gang ; Stucky, Andres ; Zhang, Xi ; Cristofanilli, Massimo ; Fatatis, Alessandro ; Gray, Joe ; Zhong, Jiang F. ; Prendergast, George C. ; Pestell, Richard G. / CCR5 Governs DNA damage repair and breast cancer stem cell expansion. In: Cancer Research. 2018 ; Vol. 78, No. 7. pp. 1657-1671.
@article{317b75c22dcf4bc488acfd16d5fc5d82,
title = "CCR5 Governs DNA damage repair and breast cancer stem cell expansion",
abstract = "The functional significance of the chemokine receptor CCR5 in human breast cancer epithelial cells is poorly understood. Here, we report that CCR5 expression in human breast cancer correlates with poor outcome. CCR5{\th} breast cancer epithelial cells formed mammospheres and initiated tumors with >60-fold greater efficiency in mice. Reintroduction of CCR5 expression into CCR5-negative breast cancer cells promoted tumor metastases and induced DNA repair gene expression and activity. CCR5 antagonists Maraviroc and Vicriviroc dramatically enhanced cell killing mediated by DNA-damaging chemotherapeutic agents. Single-cell analysis revealed CCR5 governs PI3K/Akt, ribosomal biogenesis, and cell survival signaling. As CCR5 augments DNA repair and is reexpressed selectively on cancerous, but not normal breast epithelial cells, CCR5 inhibitors may enhance the tumor-specific activities of DNA damage response–based treatments, allowing a dose reduction of standard chemotherapy and radiation. Significance: This study offers a preclinical rationale to reposition CCR5 inhibitors to improve the treatment of breast cancer, based on their ability to enhance the tumor-specific activities of DNA-damaging chemotherapies administered in that disease.",
author = "Xuanmao Jiao and Velasco-Velazquez, {Marco A.} and Min Wang and Zhiping Li and Hallgeir Rui and Peck, {Amy R.} and James Korkola and Xuelian Chen and Shaohua Xu and DuHadaway, {James B.} and Sandra Guerrero-Rodriguez and Sankar Addya and Daniela Sicoli and Zhaomei Mu and Gang Zhang and Andres Stucky and Xi Zhang and Massimo Cristofanilli and Alessandro Fatatis and Joe Gray and Zhong, {Jiang F.} and Prendergast, {George C.} and Pestell, {Richard G.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-17-0915",
language = "English (US)",
volume = "78",
pages = "1657--1671",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - CCR5 Governs DNA damage repair and breast cancer stem cell expansion

AU - Jiao, Xuanmao

AU - Velasco-Velazquez, Marco A.

AU - Wang, Min

AU - Li, Zhiping

AU - Rui, Hallgeir

AU - Peck, Amy R.

AU - Korkola, James

AU - Chen, Xuelian

AU - Xu, Shaohua

AU - DuHadaway, James B.

AU - Guerrero-Rodriguez, Sandra

AU - Addya, Sankar

AU - Sicoli, Daniela

AU - Mu, Zhaomei

AU - Zhang, Gang

AU - Stucky, Andres

AU - Zhang, Xi

AU - Cristofanilli, Massimo

AU - Fatatis, Alessandro

AU - Gray, Joe

AU - Zhong, Jiang F.

AU - Prendergast, George C.

AU - Pestell, Richard G.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The functional significance of the chemokine receptor CCR5 in human breast cancer epithelial cells is poorly understood. Here, we report that CCR5 expression in human breast cancer correlates with poor outcome. CCR5þ breast cancer epithelial cells formed mammospheres and initiated tumors with >60-fold greater efficiency in mice. Reintroduction of CCR5 expression into CCR5-negative breast cancer cells promoted tumor metastases and induced DNA repair gene expression and activity. CCR5 antagonists Maraviroc and Vicriviroc dramatically enhanced cell killing mediated by DNA-damaging chemotherapeutic agents. Single-cell analysis revealed CCR5 governs PI3K/Akt, ribosomal biogenesis, and cell survival signaling. As CCR5 augments DNA repair and is reexpressed selectively on cancerous, but not normal breast epithelial cells, CCR5 inhibitors may enhance the tumor-specific activities of DNA damage response–based treatments, allowing a dose reduction of standard chemotherapy and radiation. Significance: This study offers a preclinical rationale to reposition CCR5 inhibitors to improve the treatment of breast cancer, based on their ability to enhance the tumor-specific activities of DNA-damaging chemotherapies administered in that disease.

AB - The functional significance of the chemokine receptor CCR5 in human breast cancer epithelial cells is poorly understood. Here, we report that CCR5 expression in human breast cancer correlates with poor outcome. CCR5þ breast cancer epithelial cells formed mammospheres and initiated tumors with >60-fold greater efficiency in mice. Reintroduction of CCR5 expression into CCR5-negative breast cancer cells promoted tumor metastases and induced DNA repair gene expression and activity. CCR5 antagonists Maraviroc and Vicriviroc dramatically enhanced cell killing mediated by DNA-damaging chemotherapeutic agents. Single-cell analysis revealed CCR5 governs PI3K/Akt, ribosomal biogenesis, and cell survival signaling. As CCR5 augments DNA repair and is reexpressed selectively on cancerous, but not normal breast epithelial cells, CCR5 inhibitors may enhance the tumor-specific activities of DNA damage response–based treatments, allowing a dose reduction of standard chemotherapy and radiation. Significance: This study offers a preclinical rationale to reposition CCR5 inhibitors to improve the treatment of breast cancer, based on their ability to enhance the tumor-specific activities of DNA-damaging chemotherapies administered in that disease.

UR - http://www.scopus.com/inward/record.url?scp=85047155981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047155981&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-0915

DO - 10.1158/0008-5472.CAN-17-0915

M3 - Article

C2 - 29358169

AN - SCOPUS:85047155981

VL - 78

SP - 1657

EP - 1671

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -